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Schiff basesAbstract Six Schiff bases were prepared by reacting 3,30-diaminodipropylamine with different
benzaldehyde derivatives. The structures of these compounds were conﬁrmed through different
spectroscopic methods such as 1H-NMR, 13C-NMR and mass spectrometry. The prepared com-
pounds were evaluated in vitro for their antimicrobial activity against a number of pathogenic
Gram-positive and Gram-negative bacteria and Candida by the twofold serial dilution method.
These compounds showed bacteriostatic rather than bactericidal activities against Gram positive
and Gram-negative bacteria. In addition, compound 3c exhibited signiﬁcant anticandida activity
with an MIC of 24 lg/ml and is, therefore, considered as a promising and potential antifungal
agent; further modiﬁcation can be done on the structure of the compound for a better drug candi-
date in the future.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Nosocomial infections during the past decade have invaded hos-
pitals worldwide by multi drug resistant Gram-positive andGram-negative pathogens. Searching for novel antimicrobial
agents and new microbial targets is in demand to intervene to
avert the danger caused by these life-threatening infections
(Rachakonda and Cartee, 2004). The treatment of nosocomial
infections such as hospital acquired methicillin resistant Staph-
ylococcus aureus (MRSA) and bioﬁlm formers has become an
important problem to deal with owing to their multidrug resis-
tance (Chen et al., 2012;Maselli et al., 2012). Since the resistance
towards the available antibiotics among pathogenic bacteria has
grown rapidly, there is a clear need for the development of new
and effective antimicrobial agents. Therefore, the success in
designing antimicrobial agents which are distinct from those
Synthesis, characterization, and antimicrobial activity of Schiff bases derived from benzaldehydes and 851of the classical antibiotics is the key for treating such infectious
diseases known for their chronicity and failure to treat with con-
ventional antibiotics which will eventually lead to death.
Schiff bases have been found to possess pharmacological
activities such as antibacterial (Venugopal and Jayashree,
2008), antifungal (Pandey et al., 2003), antitubercular (Bhat
et al., 2005), antimicrobial (Wadher et al., 2009), antiviral
(Karthikeyan et al., 2006), antimalarial (Li et al., 2003) and
anticancer (Villar et al., 2004). They are important compound
due to their wide range of biological activities and industrial
application. They also serve as a back bone for the synthesis
of various heterocyclic compounds (Wang et al., 2008). The
condensing protein, (ketoacyl–acyl carrier protein synthase
(KAS), is an essential target for a novel antibacterial drug de-
sign against multidrug resistant Gram positive pathogens (Lee
et al., 2012), (Cheng et al., 2009), impressive efforts have lead
to the synthesis of peptide and Schiff bases which can be po-
tential antibiotic agents targeting KAS in Gram positive and
Gram negative pathogens.
Moreover, Schiff compounds and their metal complexes
have been of major interest for a long time because of their
ability to bind oxygen to redox systems (Muhammad et al.,
2011) exerting their ability to oxidize DNA (Landy, 1989).
They showed signiﬁcant antimicrobial activity due to the free
radical scavenging ability of their metal complexes (Al-Amiery
et al., 2012). Several research groups have been involved in the
synthesis and biological screening of Schiff bases. Kriushna-
priya et al. (2009) showed that the aldehyde Schiff base N-aryl
thiosemicarbazones had stronger anti-MRSA potency, being
effective at half the concentration of the vancomycin. Further-
more, preliminary results revealed that one of the thiazolidin-
edione-5-acetic acid amide derivatives exhibits promising
antimicrobial activity (Shankar and Kallanagouda, 2011).
Schiff bases derived from isatin derivatives and N[4-(40-chloro-
phenyl)thiozole-2-yl] thiosemicarbazide, have already provedR1
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Scheme 1 Synthesis oto be potent antimicrobial agents (Pandeya et al., 1999). Sim-
ilarly, Khanam et al. (2002) discovered that 2,20-diamino-1-
azavinyl aminoamide can be used effectively against a number
of both Gram-positive and Gram-negative bacteria. Quite re-
cently (Sadeh et al., 2011), the synthesis and characterization
of a number of new Schiff bases derived from metronidazole
have been undertaken and their antigiardial and antimicrobial
activities were evaluated.
In view of the wide interest in the activity and proﬁle of
Schiff bases derived from benzaldehydes due to their pharma-
cological interest, we described herein the synthesis and char-
acterization of six Schiff bases derived from benzaldehydes
and 3,30-diaminodipropylamine which, some of them are to
the best of our knowledge, have not previously been described
in the literature. The antimicrobial activity of the synthesized
compounds was evaluated. Also, published articles concerning
antimicrobial activity sometimes lack containing information
about the cytotoxicity of such compounds.
2. Result and discussion
2.1. Chemistry
The Schiff bases 3a–e were prepared by reacting 3,30-diamin-
odipropylamine with different benzaldehyde derivatives in eth-
anol as shown in Scheme 1. The prepared compounds were
checked for purity by TLC using glass plates precoated with
silica gel 60 GF254, supplied by Fluka as stationary phase
and suitable solvent system as mobile phase. The structures
of the prepared compounds were conﬁrmed by NMR, and
mass spectrometry. The 1H and 13C-NMR spectra of all pre-
pared compounds are in total agreement with the suggested
structures. DEPT experiments were employed to differentiate
secondary and quaternary carbons from primary and tertiary
ones. Additional supports of the proposed structures comeR2 R3
H H
H H
H OH
H H
H NO2
d Haddad, 2012)
f compounds 3a–e.
852 S.A. Matar et al.from mass spectral data; mass spectra of the prepared com-
pounds showed the correct molecular ions as suggested by
their molecular formulae. Compound 3e is soluble in water,
compound 3d is insoluble, and compounds 3a–c are partially
soluble in water. However, all of them are soluble in DMSO
and DMF and are also soluble in acidic media. Compound
3a is known in the literature while compounds 3b–e were pre-
pared as new compounds3. Biological study
3.1. Antimicrobial activity
The antimicrobial activity of the compounds against human
pathogenic Gram positive, Gram-negative bacteria and Can-
dida of 3 derivatives was measured by measuring the zone of
inhibition in disc diffusion method. Test sample per disc was
250 lg/disc.
In Table 2, measured zones of inhibition for the compounds
ranged from 0.9 to 2 cm (3a), 0.8 to 1.5 cm (4a), 1.3 to 2.1 cm
(3b), 1.1 to 2.4 cm (3c), 1.5 to 2.4 cm (3d) and 1.9 to 3 cm for
(3e) for Gram positive bacteria. Furthermore, the zone of inhi-
bition for the compounds ranged from 0.7 to 1.3 cm (3a), 0.9
to 1.1 cm (4a), 1.0 to 1.3 cm (3b), 1.0 to 2.0 cm (3c), 1.0 to
1.8 cm (3d) and 1.9 to 2.5 cm (3e) for Gram-negative bacteria.
However, the inhibition zone for the compounds against Can-
dida ranged from 0.6 to 0.8 cm (3b), 2.8 to 3.2 cm (3c), 1.7 to
2.3 cm (3d) and ﬁnally 3e ranged from 2 to 2.4 cm. Based onTable 1 Microorganism used in this study.
Gram-positive bacteria
Methicillin resistant Staphylococcus aureus (MRSA) 1168
Methicillin resistant Staphylococcus aureus (MRSA) 1052
Methicillin resistant Staphylococcus aureus (MRSA) 755
Methicillin resistant Staphylococcus aureus (MRSA) 1164
Staphylococcus epidermidis Tu 3298
Staphylococcus aureus (MSSA)
Staphylococcus aureus ATCC 25923
Staphylococcus aureus ATCC 6538
Staphylococcus aureus v329
Staphylococcus epidermidis ATCC 12228
Staphylococcus aureus ATCC 25923
Staphylococcus aureus Newman
Methicillin resistant Staphylococcus aureus small colony variants (MRSA
Methicillin resistant Staphylococcus aureus wild type (MRSA/Wild) 1204
Staphylococcus epidermidis RP62A
Staphylococcus epidermidis
Streptococcus pneumoniae
Bacillus cereus ATCC10987
Gram-Negative Bacteria
Klebsiella pneumoniae ATCC 10031
Proteus spp
Serratia spp
Escherichia coli ATCC 8739
Salmonella typhi ATCC 14026
Yeast
Candida albicans ATCC 10231zones of inhibition results, the compounds showed better activ-
ity against Gram positive bacteria than the activities against
Gram negative and Candida. The potency has increased with
a moiety of NO2 at R3 position in 3e when compared to H
and OH in the other compounds.
The previous results were in consistent with the results ob-
tained in micro dilution methods for assessing the antimicro-
bial activities for the studied compounds. The median MIC
results in Table 3 and Figure 1 showed that the median MIC
for the 3e compound had the best bacteriostatic and fungistatic
activity among the assessed compounds. The compound 3e
showed promising activity against S. aureus strains, which
are methicillin sensitive and bioﬁlm producers. The MIC ran-
ged (24–49 lg/ml).
The compound 3c derivative had a signiﬁcant activity
against Candida (24 lg/ml) when compared to its activity on
bacterial strains irrespectively to its Gram stain. The activity
was due to OH moiety at position R3 that indicates evidence
of selectivity of the ligand to the target in Candida.
The minimal bactericidal concentration for the compounds
found in Table 4 showed that the compound 3e had static
activity rather than cidal against Gram positive and Gram-
negative pathogens. These results are illustrated as no MBC
for the compound 3e. Nevertheless, MBC for 3e against one
strain of S. aureus ATCC 25923 was 48 lg/ml. This strain is
used as a laboratory standard and it is known for its suscepti-
bility to many antibiotics according to NCCLS (2003, 2006).
Finally, cytotoxicity of these compounds shows that 3a and
4a have IC50 (lg/ml) ± SD of 132 ± 1.22 and 113 ± 2.03,Origin
Clinical isolate
Clinical isolate
Clinical isolate
Clinical isolate
Bioﬁlm negative
Methicillin susceptible S. aureus
Control for antibiotic susceptibility testing
Methicillin sensitive
Bioﬁlm positive
Control for antibiotic susceptibility testing
Methicillin susceptible
Bioﬁlm positive
/SCV) 1204 Clinical isolate
Clinical isolate
Bioﬁlm positive
Clinical isolate
Clinical isolate
Control for antibiotic susceptibility testing
Control for antibiotic susceptibility testing
Clinical isolate urinary tract infections
Clinical isolate
Control for antibiotic susceptibility testing
Control for antibiotic susceptibility testing
Control for susceptibility testing
Table 2 Antimicrobial activity of various chemical compounds by disc diffusion method.
Strain Gentamicin 10 lg 3a 4a 3b 3c 3d 3e
Diameter (cm)
MRSA 1168 NI 1.2 ± 0.2 1.0 ± 0.1 1.4 ± 0.2 2.0 ± 0.2 2.1 ± 0.3 2.3 ± 0.4
MRSA 1052 NI 1.2 ± 0.4 0.8 ± 0.3 1.5 ± 0.2 2.0 ± 0.1 2.1 ± 0.3 2.5 ± 0.2
MRSA 755 NI 1.5 ± 0.2 0.8 ± 0.4 1.3 ± 0.3 1.9 ± 0.2 2.2 ± 0.3 2.5 ± 0.2
MRSA 1164 NI 1.3 ± 0.2 0.8 ± 0.2 1.3 ± 0.2 2.0 ± 0.1 2.2 ± 0.4 2.5 ± 0.1
S.epidermidis Tu 3298 3.2 ± 0.2 1.6 ± 0.2 1.0 ± 0.4 1.2 ± 0.3 2.1 ± 0.2 2.1 ± 0.3 3.0 ± 0.2
MSSA 1.8 ± 0 .1 1.6 ± 0.5 0.7 ± 0.3 2.1 ± 0.2 2.1 ± 0.3 2.2 ± 0.3 3.0 ± 0.4
S.aureus ATCC 25923 2.6 ± 0.3 2.3 ± 0.3 0.6 ± 0.4 2.1 ± 0.2 2.3 ± 0.3 2.3 ± 0.2 2.7 ± 0.2
S.aureus ATCC 6538 2.3 ± 0.1 2.3 ± 0.4 1.0 ± 0.3 2.2 ± 0.2 2.4 ± 0.2 2.2 ± 0.3 2.4 ± 0.1
S. aureus v329 2.0 ± 0.4 2.0 ± 0.2 1.2 ± 0.1 2.1 ± 0.1 2.4 ± 0.1 2.2 ± 0.3 2.5 ± 0.1
S.epidermidis ATCC 12228 3.4 ± 0.2 1.7 ± 0.4 1.5 ± 0.2 1.6 ± 0.3 1.6 ± 0.1 1.6 ± 0.2 2.0 ± 0.1
S.aureus ATCC 25923 2.4 ± 0.4 1.5 ± 0.3 1.3 ± 0.4 2.1 ± 0.2 2.3 ± 0.3 2.4 ± 0.1 2.4 ± 0.3
S. aureus Newman 2.0 ± 0.4 0.7 ± 0.3 1.2 ± 0.3 1.8 ± 0.4 1.9 ± 0.3 1.9 ± 0.1 2.5 ± 0.3
MRSA SCV 1204 NI 1.0 ± 0.4 1.0 ± 0.4 1.5 ± 0.2 1.5 ± 0.2 1.8 ± 0.2 1.9 ± 0.2
MRSA/Wild 1204 NI 1.0 ± 0.1 1.0 ± 0.3 1.6 ± 0.3 1.8 ± 0.1 1.8 ± 0.2 2.0 ± 0.2
S. epidermidis RP62A 1.5 ± 0.4 0.9 ± 0.4 1.5 ± 0.3 1.6 ± 0.2 1.6 ± 0.1 1.6 ± 0.3 2.0 ± 0.2
S. epidermidis 1.0 ± 0.3 1.0 ± 0.2 1.5 ± 0.3 1.5 ± 0.2 1.6 ± 0.2 1.6 ± 0.3 2.4 ± 0.3
S. pneumoniae 1.5 ± 0.2 2.0 ± 0.2 1.0 ± 0.1 1.6 ± 0.2 1.6 ± 0.2 1.9 ± 0.3 2.0 ± 0.3
B.cereus ATCC 10987 NI 1.0 ± 0.1 1.0 ± 0.3 1.3 ± 0.2 1.1 ± 0.2 1.5 ± 0.1 2.0 ± 0.2
K. pneumoniae ATCC 10031 NI 1.2 ± 0.1 0.9 ± 0.2 1.0 ± 0.2 1.3 ± 0.1 1.7 ± 0.2 1.9 ± 0.2
Proteus spp 1.6 ± 0.1 1.2 ± 0.1 1.0 ± 0.2 1.0 ± 0.2 1.2 ± 0.2 1.0 ± 0.2 1.9 ± 0.2
Serratia spp 2.0 ± 0.3 0.7 ± 0.4 1.0 ± 0.1 1.1 ± 0.2 1.0 ± 0.2 1.3 ± 0.2 2.0 ± 0.1
E. coli ATCC 8739 2.0 ± 0.3 1.3 ± 0.3 1.1 ± 0.1 1.3 ± 0.3 2.0 ± 0.1 1.8 ± 0.3 2.5 ± 0.3
S. typhi ATCC 14026 2.2 ± 0.1 1.2 ± 0.1 1.1 ± 0.3 1.3 ± 0.1 1.2 ± 0.1 1.3 ± 0.1 2.0 ± 0.2
C. albicans 1.5 ± 0.4a 0.6 ± 0.1 NI 0.7 ± 0.1 3.0 ± 0.2 2.0 ± 0.3 2.2 ± 0.2
The results are the mean ± SD (n= 3).
a This is the diameter of Nystatin disc (25 lg) against Candida. NI, No inhibition zone; DMSO, NI.
Table 3 Minimum inhibition concentration (MIC) for the compounds against different organisms.
Strains Gentamicin (10 lg) 3a 4a 3b 3c 3d 3e
MIC (lg/ml)
MRSA 1168 500 800 1250 1500 3100 1500 200
MRSA 1052 500 800 1250 1500 3100 1500 200
MRSA 755 500 800 1250 1500 3100 1500 200
MRSA 1164 500 800 1250 1500 3100 1500 200
S.epidermidis Tu 3298 0.5 400 1250 800 1500 800 24
MSSA 0.5 400 700 1500 200 1900 24
S.aureus ATCC 25923 0.5 400 700 1500 1500 1500 24
S.aureus ATCC 6538 0.5 800 2500 800 800 800 97
S. aureus v329 0.5 200 13800 15600 1500 1500 49
S.epidermidis ATCC 12228 0.5 400 700 900 400 800 24
S.aureus ATCC 25923 0.5 800 1250 1500 400 1500 48
S. aureus Newman 0.5 800 2500 1500 200 1500 48
MRSA SCV 1204 2500 1250 1270 1500 3100 1500 400
MRSA/Wild 1204 600 1250 1270 1500 3100 1500 200
S. epidermidis RP62A 0.5 400 700 800 200 1500 24
S. epidermidis 0.5 400 700 800 200 800 49
S. pneumoniae 0.5 800 1250 200 200 200 98
B.cereus ATCC 10987 ND 700 800 800 800 800 400
K. pneumoniae ATCC 10031 ND 800 1250 1500 1500 800 400
Proteus spp 1.3 800 1200 800 3120 1500 200
Serratia spp 1.6 400 3400 1500 3120 1500 200
E. coli ATCC 8739 1 200 1250 1500 400 1500 24
S. typhi ATCC 14026 1 400 2750 1500 3120 1500 200
C. albicans 6a NA NA 4000 24 400 97
a Nystatin used as control. NA, no activity; ND, not determined. Bold font indicates signiﬁcant results.
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IC50 greater than 200 lg/ml.Finally, further study should be done on the mode of action
of these compounds to elucidate the structure–function
Table 4 Minimum bactericidal/fungicidal concentration (MBC/MFC in lg/ml) for the compounds against different organisms.
Strains Gentamicin 3a 4a 3b 3c 3d 3e
MBC/MFC in (lg/ml)
MRSA 1168 2500 1560 2500 3000 NO MBC 1560 NO MBC
MRSA 1052 2500 1560 5000 2500 NO MBC NO MBC NO MBC
MRSA 755 2500 1560 2500 6250 6250 1560 1560
MRSA 1164 2500 1560 2500 3120 6250 1560 NO MBC
S.epidermidis Tu 3298 2 800 2500 3120 3120 1560 NO MBC
MSSA 2 800 1200 1560 NO MBC 1500 1500
S.aureus ATCC 25923 2 800 13800 31200 3120 3120 3120
S.aureus ATCC 6538 2 800 2500 800 NO MBC 1560 400
S. aureus v329 2 400 NO MBC 3120 3120 3120 NO MBC
S.epidermidis ATCC 12228 2 800 1200 1560 800 1560 NO MBC
S.aureus ATCC 25923 2 1560 2500 1560 800 NO MBC 48
S. aureus Newman 2 1560 2500 1500 NO MBC 1560 NO MBC
MRSA SCV 1204 >2500 800 1560 1560 NO MBC 1560 NO MBC
MRSA/Wild 1204 2500 400 1560 1560 1560 1560 NO MBC
S. epidermidis RP62A 2 800 1200 3120 400 3100 NO MBC
S. epidermidis 2 3000 1200 1560 800 1560 NO MBC
S. pneumoniae 2 1500 2500 400 400 NO MBC 400
B.cereus ATCC 10987 NDc 1560 2500 1560 3125 3125 800
K. pneumoniae ATCC 10031 ND 1500 5000 1560 1560 1560 800
Proteus spp 7 1500 2500 NO MBC 6000 3120 400
Serratia spp 6 1500 5000 NO MBC 12500 3120 NO MBC
E. coli ATCC 8739 5 400 2500 6200 800 NO MBC NO MBC
S. typhi ATCC 14026 5 400 5000 NO MBC 12500 3120 NO MBC
C. albicans 30a NAb NA NO MBC 200 800 400
a Nystatin used as a control.
b NA, no activity.
c ND, not determined.
854 S.A. Matar et al.relationship. Based on a study published on some Schiff base
complexes (Joseyphus and Nair, 2008), it was suggested that
the mode of action may involve various targets in microorgan-
isms. These mechanisms can be classiﬁed into four points: (1)
the interference with the cell wall synthesis as a result the cell
permeability may be altered or they may disorganize the lipo-
proteins leading to cell death, (2) Deactivate various cellular
enzymes which are important in the microorganism’s meta-
bolic pathways, (3) Formation of a hydrogen bond through
the azomethine group with the active centres of cell constitu-
ents resulting in interfering with the normal cell processes,
(4) Denaturation of one or more proteins of the cell, as a result
of which the normal cellular processes are impaired.
Due to the similarities in structures with the substances
studied by (Joseyphus and Nair, 2008), we might speculate that
one of the previously suggested targets could be considered for
our compounds. But our speculation should be supported by
biochemical studies in the future.
4. Conclusion
In conclusion, four Schiff bases were synthesized by reacting
3,30-diaminodipropylamine with benzaldehyde and some other
derivatives. Three of the prepared compounds were prepared
for the ﬁrst time. The structures of the prepared compounds
were conﬁrmed by different spectroscopic methods and the
antimicrobial activity was assessed. The compounds were
tested against a large number of pathogenic strains of Gram-
positive, Gram-negative bacteria and Candida. Compound
3e exhibited good growth inhibition activity againstpathogenic microorganisms and Candida and is promising to
act as a potential antimicrobial agent. Results also revealed
that compound 3c showed moderate activity against Candida;
further structural modiﬁcations could lead to a promising anti-
candida agent. Based on the results obtained, slight modiﬁca-
tions of the structures might produce potent and potential
compounds which could be used as anticandida drugs, espe-
cially if further work proves that cytotoxicity of the prepared
Schiff bases is less than the drug, Nystatin.
5. Experimental section
5.1. Chemistry
The following chemicals, used in this study, were purchased
from Acros and were used as received: 3,30-diaminodipropyl-
amine, benzaldehyde, 2-hydroxybenzaldehyde, 2,4-dihydroxy-
benzaldehyde, 2,3,4-trihydroxybenzaldehyde, 4-nitrobenzal
dehyde and 2-methoxybenzaldehyde. Silica gel for column
chromatography was purchased fromMacherey–Nagel GmbH
& Co (Germany). Melting points (uncorrected) were deter-
mined on a Stuart scientiﬁc melting point apparatus in open
capillary tubes. 1H- and 13C-NMR spectra were recorded on
a 300 MHz spectrometer (Bruker DPX-300) with TMS as
the internal standard. Chemical shifts are expressed in d units;
J-values for 1H–1H coupling constant are given in Hertz. High-
resolution mass spectra (HRMS) were acquired (in positive or
negative mode) using electrospray ion trap (ESI) technique by
collision-induced dissociation with the aid of a Bruker
APEX-4 (7-Tesla) instrument. The samples were dissolved in
Synthesis, characterization, and antimicrobial activity of Schiff bases derived from benzaldehydes and 855acetonitrile, diluted in spray solution (methanol/water 1:1 v/
v + 0.1% formic acid) and infused using a syringe pump with
a ﬂow rate of 2 lL/min. External calibration was conducted
using arginine cluster in a mass range m/z 175–871.
5.1.1. General procedure for preparation of compounds 3a–e
Compounds 3a–e were prepared according to a published
procedure that involved adding 3,30-diaminodipropylamine
(3.0 ml, 21 mmol), drop wise, to a solution of the corre-
sponding aldehyde (42 mmol) in absolute ethanol (25 ml).
The mixture was reﬂuxed for 4 h. Evaporation of the solvent
under reduced pressure afforded the desired product in 80–
93% yield. The product was washed with water, dried and
puriﬁed on preparative silica gel TLC plates. In case of
4a, the synthesis of such salts is difﬁcult, we obtained this
salt by gently heating one equivalent of cyanuric acid with
three equivalents of 3a in EtOH and the salt was character-
ized as monochloride. Recently, AlDamen and Haddad
(AlDamen and Haddad, 2012) published the crystal struc-
ture of this compound.
5.1.2. 2,20-{iminobis[(1E)prop-3-yl-1-
ylidene(E)azanylylidene]}diphenol (3a)
Yield = 90%, yellow oil. 1H-NMR (300 MHz, DMSO-d6) d:
1.99 (m, 4H, CH2CH2NH), 2.42 (m, 1H, NH), 2.95 (m, 4H,
CH2NH), 3.63 (m, 4H, CH‚NCH2), 6.85 (m, 4H, H-3 + H-
5), 7.28 (t, J= 7.8 Hz, 2H, H-4), 7.39 (d, J= 7.5 Hz, 2H,
H-6), 8.56 (s, 2H, CH‚N), 8.71 (br m, 2H, OH). 13C-NMR
(75 MHz, DMSO-d6) d: 31.51 (CH2CH2CH2), 45.3 (NH–C),
55.9 (‚N–C), 116.9 (C-3), 119.1 (C-5), 123.9 (C-1), 132.2
(C-6), 132.9 (C-4), 160.6 (HC‚N), 167.0 (C-2). HRMS
(ESI) m/z: Calcd for C20H26N3O2 [M+H]
+ 340.20250; found
340.20293.5.1.3. (3E)-3-[(2-methoxyphenyl)imino]-N-{(3E)-3-[(2-
methoxyphenyl)imino]propyl}propan-1-amine (3b)
Yield = 80%, pale yellow oil. 1H-NMR (300 MHz, DMSO-
d6) d: 1.79 (m, 4H, CH2CH2NH), 2.46 (m, 4H, CH2NH),
3.45 (m, 4H, CH‚NCH2), 3.87 (s, 3H, OCH3), 6.91 (m, 2H,
H-5), 7.03 (d, J= 8.1 Hz, 2H, H-3), 7.38 (m, 2H, H-4), 7.58
(d, J= 7.7 Hz, 2H, H-6), 8.45 (s, 1H, HC‚N). 13C-NMR
(75 MHz, DMSO-d6) d: 31.1 (CH2CH2CH2), 47.0 (NH–
CH2), 54.5 (‚N–CH2), 110.4 (C-3), 119.7 (C-5), 120.0 (C-1),
126.1 (C-6), 131.0 (C-4), 158.2 (C-2) 149.6 (C-4), 158.8
(HC‚N). HRMS (ESI) m/z: Calcd for C22H30N3O
[M+H]+ 368.23380; found 368.23325.
5.1.4. 4,40-{iminobis[(1E)prop-3-yl-1-
ylidene(E)azanylylidene]}dibenzene-1,3-diol (3c)
Yield = 84%, m.p. = 335–338 C. 1H-NMR (300 MHz,
DMSO-d6) d: 1.67 (m, 4H, CH2CH2NH), 2.40 (br m, 1H,
NH), 2.48 (m, 4H, CH2NH), 3.46 (m, 4H, CH‚NCH2),
4.51 (br s, 4H, OH). 6.09 (d, J= 2.0 Hz, 2H, H-3), 6.17
(dd, J= 9.0, 2.0 Hz, 2H, H-5) 7.09 (d, J= 9.0 Hz, 2H,
H-4), 8.21 (s, 2H, CH‚N). 13C-NMR (75 MHz, DMSO-
d6) d: 31.0 (CH2CH2CH2), 47.2 (NH–C), 54.6 (‚N–C),
103.3 (C-3), 107.2 (C-5), 111.5 (C-1), 133.8 (C-6), 162.8
(HC‚N), 164.8 (C-4), 166.6 (C-2). HRMS (ESI) m/z:
Calcd for C20H26N3O4 [M+ H]
+ 372.19233; found
372.19178.5.1.5. (3E)-3-(phenylimino)-N-[(3E)-3-
(phenylimino)propyl]propan-1-amine (3d)
Yield = 93%, m.p. = 62–64 C. 1H-NMR (300 MHz, CDCl3)
d: 1.76 (m, 4H, CH2CH2NH), 2.40 (m, 4H, CH2NH), 2.42 (m,
1H, NH), 3.47 (m, 4H, CH‚NCH2), 7.55 (m, 6H, H-3 + H-
4 + H-5), 7.75 (d, J= 7.7 Hz, 4H, H-2 + H-6), 8.25 (s, 2H,
CH‚N). 13C-NMR (75 MHz, CDCl3) d: 31.3 (CH2CH2CH2),
45.4 (NH–C), 58.0 (‚N–C), 128.3 (C-3/C-5), 129.2 (C-2/C-6),
131.4 (C-4) 137.6 (C-1), 159.9 (HC‚N). HRMS (ESI) m/z:
Calcd for C20H26N3 [M+H]
+: 308.21267; found 308.21306.
5.1.6. (3E)-3-[(4-nitrophenyl)imino]-N-{(3E)-3-[(4-
nitrophenyl)imino]propyl}propan-1-amine (3e)
Yield = 83%, m.p. = 86–88 C. 1H-NMR (300 MHz, CDCl3)
d: 1.76 (m, 4H, CH2CH2NH), 2.32 (m, 4H, CH2NH), 2.35 (br
s, 1H, NH), 3.43 (m, 4H, CH‚NCH2), 7.58 (d, J= 8.7 Hz,
2H, H-2 + H-6), 7.70 (d, J= 8.7 Hz, 2H, H-3 + H-5), 8.21
(s, 1H, HC‚N). 13C-NMR (75 MHz, CDCl3) d: 27.8
(CH2CH2CH2), 45.5 (NH–C), 59.2 (‚N–C), 123.8 (C-3/C-
5), 128.6 (C-2/C-6), 141.5 (C-1) 149.6 (C-4), 158.8 (HC‚N).
HRMS (ESI) m/z: Calcd for C22H30N3O [M+H]
+
368.23380; found 368.23325. HRMS (ESI) m/z: Calcd for
C20H24N5O4 [M+H]
+ 398.18283; found 398.18198.
5.2. Microbiological procedures
5.2.1. Bacterial culture
About 24 bacterial strains included in this study were from
American Type Culture Collection (ATCC) (Rockville, MD
and USA), clinical isolates were obtained from Asem A. She-
habi (Professor of Microbiology, University of Jordan) and
staphylococcal bioﬁlm mutant strains from Jose´ R. Penade´s
Senior Researcher at the Consejo Superior de Investigaciones
Cientı´ﬁcas, Spain. There was one Candida strain (ATCC) in-
cluded in this study was a gift from Basem Jaber (Assistant
professor of mycology, The University of Jordan). All the
strains were conﬁrmed by cultural and biochemical character-
istics and maintained in slants for further use. The bacterial
strains were either Gram positive or Gram negative. These
organisms are found in Table 1.
5.3. Antimicrobial activity
5.3.1. Disc diffusion method
The synthetic compound 3was tested in vitro for their antimicro-
bial activity against Gram positive and Gram-negative organ-
isms and Candida at 0.02 g/ml, respectively by Kirby–Bauer
agar diffusion method (Bauer et al., 1966). The current NCCLS
(CLSI document M2-A9, 2006)guidelines recommend using
Mueller–Hinton agar medium for bacteria and Sabouraud dex-
trose agar medium for Candida (NCCLS-M27-A 1997).
Brieﬂy, 100 ll of the test bacteria/Candida was grown in
10 ml of fresh media until they reached a count of ca.
108 cells/ml for bacteria (0.5 McFarland standards), One hun-
dred microlitre (100 ll) of microbial suspension was spread
onto the Mueller–Hinton agar medium.
The compounds were tested using 6 mm sterilized ﬁlter pa-
per discs (antibiotic assay discs, Whatman-model 2017-006) as
mentioned before (Antonio-Velmonte et al., 1988). Discs were
impregnated with 25 lL of 0.02 g/ml of the compound and al-
lowed to dry and placed onto inoculated plates. The plates
856 S.A. Matar et al.were allowed to stand at 4 C for 2 h before incubation with
the test microbial agents. Inoculated plates with different path-
ogenic bacteria and Candida were incubated at 37 C for 24 h,
and then the diameters of the inhibition zones were measured
in centimetres. Each antimicrobial assay was performed in
triplicate and mean values were reported. Standard antibiotics,
gentamicin (10 lg/disc), and nystatin 25 lg/disc served as posi-
tive controls for antimicrobial and Candida activity, respec-
tively. Filter discs impregnated with 10 ll of distilled water
were used as a negative control. Solvent control disc (DMSO)
was also placed with the test as a negative control. The inhibi-
tion zone diameters were measured. The inhibitory effects of
the synthetic compounds against these organisms are given
in Table 2.
5.3.2. Serial dilution method (broth microdilution assay)
A broth microdilution method was employed to determine the
minimum inhibition concentration (MIC) and minimum bacte-
ricidal/fungicidal concentration (MBC/MFC) according to the
National Committee for Clinical Laboratory Standards
(NCCLS, Document M100–S11, 2003). The inocula of the
bacterial strains or Candida were prepared from overnight
broth cultures and suspensions were adjusted to 0.5 McFar-
land standard turbidity. A serial doubling dilution of the com-
pounds was prepared in a 96/well microtiter plate. A double
strength of Mueller Hinton broth was used as a diluent. The
concentrations were in range of 20–0.006 mg/ml for the com-
pounds. Bacterial strains and Candida tested were inoculated
in Mueller Hinton broth and inoculated into wells (the ﬁnal
concentration in each well adjusted to 2.0 · 106 CFU/ml for
bacteria and 2.0 · 105 of Candida strains). The plate was incu-
bated for 24 h at 37 C. A control well containing the growth
medium and the bacteria or Candida was set-up. Gentamicin
and Nystatin served as positive controls, while the solvent
(DMSO) was used as a negative control. MIC was deﬁned as
the lowest concentration of compound at which micro organ-
isms show no visible growth as shown in Table 3. To determine
MBC/MFC broth was taken from each well and inoculated on
Mueller Hinton agar for 24 h at 37 C for bacteria or in Sab-
ouraud dextrose agar for Candida strains. The results were ob-
tained for MBC/MFC as the lowest concentration of antibiotic
required to kill the organism as indicated in Table 4.5.3.3. Cytotoxicity study
The Vero cell line was used to determine the cytotoxicity of
compounds included in this investigation. Vero cells were
grown in Minimum Essential Medium Eagle (MEM) (Gibco,
UK) supplemented with 10% heat inactivated fetal bovine ser-
um (Gibco, UK), 29 lg/ml L-glutamine, and 40 lg/ml gentami-
cin and were incubated in a humidiﬁed atmosphere of 5% CO2
at 37 C. The cytotoxicity of compounds was measured using
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay (Promega, USA). The assay detects the reduc-
tion of MTT by mitochondrial dehydrogenase to blue forma-
zan product, which reﬂects the normal function of
mitochondria and cell viability (Lau et al., 2004). Eight con-
centrations (200, 150, 100, 50, 25, 12, 6, and 3 lg/ml) were pre-
pared from each compound. Exponentially growing Vero cells
were washed and seeded at 17000 cells/well (in 200 ll of
growth medium) in 96 well microplates (Nunc, Denmark).
After 24 h incubation, a partial monolayer was formed thenthe medium was removed and 200 ll of the medium containing
the compound (initially dissolved in DMSO) was added and
re-incubated for 48 h. Then 100 ll of the medium was aspi-
rated and 15 ll of the MTT solution was added to the remain-
ing medium (100 ll) in each well. After 4 h contact with the
MTT solution, blue crystals were formed. 100 ll of the stop
solution was added and incubated further for 1 h. Reduced
MTT was assayed at 650 nm using a microplate reader (Das,
Italy). Control groups received the same amount of DMSO
(0.1%). Untreated cells were used as a negative control.
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